Pfizer (PFE, $43.46) beats Q4 earnings estimates, but projects 2023 sales decline
Pfizer Inc. shares fell Tuesday, after the drugmaker posted fourth quarter earnings that surpassed analysts’ expectations while issuing a softer 2023 growth guidance amidst cooling off of its Covid treatments’ sales.
Pfizer’s adjusted earnings for the three months ending in December came in at $1.14 per share, beating the Street consensus forecast of $1.05 per share. Revenues climbed +2% year-over-year to $24.3 billion, in line with analysts' estimates.
For 2023 financial year, Pfizer expects revenue to decrease in 2023 by as much as 33% to a range of $67 billion to $71 billion as the world emerges from the pandemic. It projects around -64% decline in sales of its Covid vaccine (Comirnaty) to $13.5 billion, and -58% drop in sales of antiviral treatment Paxlovid to $8 billion.
PFE's RSI Oscillator ascending out of oversold territory
The RSI Oscillator for PFE moved out of oversold territory on November 22, 2024. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 46 similar instances when the indicator left oversold territory. In of the 46 cases the stock moved higher. This puts the odds of a move higher at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on December 17, 2024. You may want to consider a long position or call options on PFE as a result. In of 79 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for PFE just turned positive on November 26, 2024. Looking at past instances where PFE's MACD turned positive, the stock continued to rise in of 41 cases over the following month. The odds of a continued upward trend are .
PFE moved above its 50-day moving average on December 23, 2024 date and that indicates a change from a downward trend to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where PFE advanced for three days, in of 263 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The 50-day moving average for PFE moved below the 200-day moving average on December 05, 2024. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PFE declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
PFE broke above its upper Bollinger Band on December 23, 2024. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for PFE entered a downward trend on November 26, 2024. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.763) is normal, around the industry mean (5.632). P/E Ratio (74.919) is within average values for comparable stocks, (48.974). Projected Growth (PEG Ratio) (0.281) is also within normal values, averaging (3.004). Dividend Yield (0.060) settles around the average of (0.164) among similar stocks. P/S Ratio (2.674) is also within normal values, averaging (3.643).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. PFE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PFE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 76, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
General Information
a manufacturer of vaccines and injectable biologic medicines
Industry PharmaceuticalsMajor